Biblio

24 resultats trouvés
Filtres: Auteur is Lacombe, Karine  [Clear All Filters]
A
Garraud O, Lacombe K, Tiberghien P.  2021.  A look-back at convalescent plasma to treat COVID-19. TRANSFUSION AND APHERESIS SCIENCE. 60:103063.
Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A, Esterle L, Chas J, Poizot-Martin I et al..  2016.  All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. CLINICAL INFECTIOUS DISEASES. 63:763-770.
Tan BKim, Chalouni M, Ceron DSalmon, Cinaud A, Esterle L, Loko MArthur, Katlama C, Poizot-Martin I, Neau D, Chas J et al..  2021.  Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. CLINICAL INFECTIOUS DISEASES. 72:ciaa1014.
C
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y.  2020.  Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? VOX SANGUINIS. 115:488-494.
Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y.  2020.  Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? VOX SANGUINIS. 115:488-494.
Hueso T, Pouderoux C, Pere H, Beaumont A-L, Raillon L-A, Ader F, Chatenoud L, Eshagh D, Szwebel T-A, Martinot M et al..  2020.  Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. BLOOD. 136:2290-2295.
D
Lamure S, Dulery R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, Drenou B, Soussain C, Rossi C, Noel N et al..  2020.  Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. ECLINICALMEDICINE. 27:100549.
E
Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A et al..  2017.  Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. JOURNAL OF HEPATOLOGY. 67:23-31.
Miailhes P, Boyd A, Chas J, Rougier H, Valantin M-A, Yazdanpanah Y, Rosenthal E, Guidoum A, Pialoux G, Piroth L et al..  2018.  Efficacy and Tolerability of 8-Week Grazoprevir/Elbasvir to Treat Acute Hepatitis C Virus Infection in Men Who Have Sex with Men: An Interim Analysis of the Sahiv Study. HEPATOLOGY. 68:367A-368A.
Barre T, Protopopescu C, Bani-Sadr F, Piroth L, Rojas TRojas, Salmon-Ceron D, Wittkop L, Esterle L, Sogni P, Lacombe K et al..  2020.  Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). HEPATOLOGY. 71:1182-1197.
F
Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G et al..  2018.  Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. WORLD JOURNAL OF HEPATOLOGY. 10:856-866.
Shili S, Wittkop L, Sogni PS, de Ledinghen V, Esterle L, Valantin M-A, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K et al..  2016.  Factors associated with mortality, independently of sustained virological response (SVR), in HIV/HCV co-infected subjects - ANRS CO13 HEPAVIH cohort.. HEPATOLOGY. 64:29A-30A.
Shili S, Wittkop L, Sogni PS, de Ledinghen V, Esterle L, Valantin M-A, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K et al..  2016.  Factors associated with mortality, independently of sustained virological response (SVR), in HIV/HCV co-infected subjects - ANRS CO13 HEPAVIH cohort.. HEPATOLOGY. 64:29A-30A.
G
Boyd A, Miailhes P, Chas J, Valantin M-A, Yazdanpanah Y, Rosenthal E, Chevaliez S, Piroth L, Rougier H, Peytavin G et al..  2020.  Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 75:1961-1968.
H
Piroth L, Paniez H, Taburet AMarie, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F et al..  2015.  High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. CLINICAL INFECTIOUS DISEASES. 61:817-825.
Lamure S, Dulery R, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau-Fischer B, Soussain C et al..  2020.  High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy.. CLINICAL CANCER RESEARCH. 27
Lamure S, Dulery R, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau-Fischer B, Soussain C et al..  2020.  High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy.. CLINICAL CANCER RESEARCH. 27
I
Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin M-A, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G et al..  2019.  Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. PLOS ONE. 14:e0211286.
L
Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L et al..  2019.  Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 31:1387-1396.
P
Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Delgado MBeso, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R et al..  2019.  Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. LIVER INTERNATIONAL. 39:136-146.
R
Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong M-A, Duvivier C, Launay O, Karmochkine M, Arvieux C et al..  2019.  ``Real life'' use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. PLOS ONE. 14:e0216010.
Chalouni M, Wittkop L, Bani-Sadr F, Lacombe K, Esterle L, Gilbert C, Miailhes P, Zucman D, Valantin MAntoine, Bregigeon-Ronot S et al..  2021.  Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. HIV MEDICINE. 22:791-804.
T
Piroth L, Pol S, Miailhes P, Lacombe K, Lopes A, Fillion A, Loustaud-Ratti V, Borsa-Lebas F, Salmon D, Rosenthal E et al..  2015.  Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study LIVER INTERNATIONAL. 35:1950-1958.
U
Salmon-Ceron D, Arvieux C, Bourliere M, Cacoub P, Halfon P, Lacombe K, Pageaux G-P, Pialoux G, Piroth L, Poizot-Martin I et al..  2014.  Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1. LIVER INTERNATIONAL. 34:869-889.